GSK

Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board

Retrieved on: 
Thursday, June 30, 2022
Yee, Department, Melanoma, Schizophrenia, Patient, Achilles, MD Anderson Cancer Center, Biotechnology, GSK, Novartis, Oncology, GLOBE, Division, Google, Company, SAB, AbbVie, Monroe Dunaway Anderson, Genentech, NSCLC, Biological E. Limited, Coronavirus Scientific Advisory Board (Turkey), ACHL, Verily, Center, University, DNA, AstraZeneca, NASDAQ, Large-cell lung carcinoma, Neurocrine Biosciences, Therapy, Pharmaceutical industry, Medical imaging, Takeda, MD, Pfizer

LONDON, June 30, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of James Taylor as Chief Business Officer and Cassian Yee, MD to its Scientific Advisory Board (SAB), effective July 1, 2022.

Key Points: 
  • LONDON, June 30, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of James Taylor as Chief Business Officer and Cassian Yee, MD to its Scientific Advisory Board (SAB), effective July 1, 2022.
  • James brings over 25 years of value-creating deal experience that includes global platform and asset deals for pharmaceutical and biotechnology companies.
  • Achilles has pioneered clonal neoantigen-targeted therapy and AI-powered bioinformatics, offering the potential to unlock therapeutic capabilities that I believe will have a tremendous impact for patients, commented James Taylor, incoming Chief Business Officer at Achilles Therapeutics.
  • The Company has also expanded its Scientific Advisory Board with the addition of Cassian Yee, MD.

Greater Philadelphia Region Seeks ARPA-H Home

Retrieved on: 
Wednesday, June 29, 2022
Drexel University, Wistar Institute, Bangladesh Technical Education Board, FDA, Chamber, Patient, Coriell Institute for Medical Research, RNA transfection, GSK, Children's Hospital of Philadelphia, HHS, Jefferson Health, Research, Senior, Johnson & Johnson, COVID-19, Commerce, International airport, Atmosphere, ARPA, NIH, PHL, Temple University, Institute for Economic Competitiveness, Letter, DARPA, Hospital, Bristol Myers Squibb, Gene editing, University, AstraZeneca, Congress, Philadelphia International Airport, Vaccine, Intention, Pharmaceutical industry, Merck, Delaware Valley, Pfizer

PHILADELPHIA, June 29, 2022 /PRNewswire/ -- The Chamber of Commerce for Greater Philadelphia today announced the region's intention to seek to be the new home for a recently announced $1 billion federal agency, the Advanced Research Projects Agency for Health (ARPA-H), which is expected to be located outside of Washington D.C.  In a letter sent to the U.S. Health & Human Services Department Secretary Xavier Becerra and signed by business, civic, and elected officials, signers tout the region's expertise in cell & gene therapy and gene editing, its rank as one of the top eight life sciences markets in the U.S., and its deep scientific and medical ecosystem as reasons why this area stands out as the ideal location. The new agency, established by Congress earlier this year, will speed up biomedical and health cures and treatment by funding new and innovative research.

Key Points: 
  • "We feel that Greater Philadelphia's position as a global hub of research, talent, capital, and companies, combined with its second-to-none accessibility, give this region the power to forever transform how care is delivered to patients and essentially cure the incurable," the letter states.
  • "Today the Chamber is launching a multi-state, eleven-county regional effort to attract the new Advanced Research Projects Agency for Health to the Greater Philadelphia region," said Claire Marrazzo Greenwood, Executive Director and Senior Vice President of Economic Competitiveness for the Chamber.
  • The Philadelphia region has a long and deep track record of innovation.
  • To date, six FDA-approved cell & gene therapies have their origins in the region.

Reach3 Insights Launches Health Practice

Retrieved on: 
Wednesday, June 29, 2022
Insurance, Consulting, Advertising, Communications, Professional Services, Biotechnology, Health, Pharmaceutical, General Health, Medical device, Insurance, Perkins, RNA transfection, CEO, GSK, De-escalation, Founder CEO, Research, Technology, Problem solving, Intelligence, Phoenix, Marketing, Medicine, Washington University in St. Louis, Health care, Huntsville Hospital System, Health, Doctor of Philosophy, Human, Financial services, Solution, Insight, CPG, Infection, Creativity, Pharmaceutical industry, Sanofi

The new Health practice will round out Reach3s industry-specific insight teams, which currently include Technology & Media, CPG, Retail and Financial Services.

Key Points: 
  • The new Health practice will round out Reach3s industry-specific insight teams, which currently include Technology & Media, CPG, Retail and Financial Services.
  • The health industry is one of the biggest consumers of marketing intelligence and includes Pharma/Biotech, Hospital Systems, Health Insurers, Medical Devices and other ancillary health services.
  • With the addition of Palmer and Perkins, this practice will serve the industrys need for applying more innovative methods to uncovering critical business insights.
  • Since launching Reach3 Insights just over 4 years ago, weve been amazed at client demand for our immersive mobile messaging-based insight solutions that enable companies to get closer to the context driving human behaviors, said Founder & CEO of Reach3 Insights, Matt Kleinschmit.

GSK Selects Target the Future Grant Recipient in Innovation Challenge Supporting Multiple Myeloma Community

Retrieved on: 
Wednesday, June 29, 2022
Professional Services, Oncology, Philanthropy, DEI (Diversity, Equity and Inclusion), Health, Foundation, Annual report, Science, Patient, Color, Life, CEO, Caregiver, GSK, COVID-19, Population, Company, Disease, Future, Awareness, Black, Genta (company), Antibody, Survival, Health, Quality of life, Equity, Multiple myeloma, Language, Think tank, Diversity, Creativity, Program, Education, Medicine, Medical imaging, Pharmaceutical industry

Their proposal, the HealthTree Equity and Diversity for Multiple Myeloma Program, will improve access, education and support for underserved communities and minority patients.

Key Points: 
  • Their proposal, the HealthTree Equity and Diversity for Multiple Myeloma Program, will improve access, education and support for underserved communities and minority patients.
  • GSK saw problems and created a program to target a better future.
  • Target the Future is an international, multi-year initiative dedicated to advancing innovation and addressing key needs in the multiple myeloma community.
  • GSK assembled a multidisciplinary advisory group of people personally and professionally connected to the multiple myeloma community and evaluated the top 20 submissions from around the world.

European Nephrologists Lead the Way with Adoption of Astellas/FibroGen's HIF-PH inhibitor, EVRENZO (roxadustat), for Anemia of CKD Treatment in Both Dialysis and Non-Dialysis Settings, Spherix Report Finds

Retrieved on: 
Wednesday, June 29, 2022
Review, Nephrology, FDA, Patient, European Medicines Agency, GSK, National Institute for Health and Care Excellence, Adoption, National Institute, Dialysis, Food and Drug Administration, ESA, EMA, Anemia, Food, NICE, Q2, HCP, Peritoneal dialysis, CKD, Safety, Pharmaceutical industry, Medical device, Roxadustat

EXTON, Pa., June 29, 2022 /PRNewswire/ -- The European regulatory authorities tend to be moving in a different direction than U.S. Food and Drug Administration (FDA) regarding novel HIF-PH inhibitor agents. Recent Spherix research provides insights from nephrologists across the EU5 regarding their view of the evolving anemia treatment landscape, including early use of first-in-class Evrenzo (roxadustat) and anticipated future use.

Key Points: 
  • Recent Spherix research provides insights from nephrologists across the EU5 regarding their view of the evolving anemia treatment landscape, including early use of first-in-class Evrenzo (roxadustat) and anticipated future use.
  • Compared to six months ago, EU5 nephrologists report the percentage of dialysis and CKD non-dialysis patients prescribed Evrenzo has at least doubled.
  • CKD non-dialysis patients, and those who are specifically ESA nave, are the most ideal candidates for Evrenzo, according to surveyed nephrologists.
  • However, home dialysis and peritoneal dialysis patients also serve as an opportunity for increased use of the drug.

New Board of Directors at Data Dynamics: Agam Upadhyay, Global CTO from GSK (Formerly GlaxoSmithKline)

Retrieved on: 
Tuesday, June 28, 2022
Board of directors, CEO, GSK, Technology, Eli Lilly and Company, Johnson & Johnson, Corporation, Company, Industry, Data management platform, Agam, BNY Mellon, Compliance, Ernst & Young, ERP, Organization, Data management, Solution, GlaxoSmithKline, Board, GrapeCity, Management

Agam will join industry veterans David Reilly, Andy Monshaw, Randy Seidl, and Henri Richard on the Data Dynamics Board.

Key Points: 
  • Agam will join industry veterans David Reilly, Andy Monshaw, Randy Seidl, and Henri Richard on the Data Dynamics Board.
  • "We are honored and pleased to welcome Agam Upadhyay to our Board of Directors," said Piyush Mehta, CEO of Data Dynamics.
  • "We are delighted to welcome Agam Upadhyay to the Board," said Andy Monshaw, Chairman of the Board, Data Dynamics.
  • Data Dynamics is a leading provider of enterprise data management solutions, helping organizations structure unstructured data with their Unified Unstructured Data Management Platform.

CardieX Announces CONNEQT Pulse, the World's First Customizable Dual Blood Pressure and Arterial Health Monitor

Retrieved on: 
Tuesday, June 28, 2022
Patient, Kuwait Central Blood Bank, Heart, Pre-eclampsia, Research, Adoption, Index, COVID-19, Company, Coronary circulation, Food, Heart rate, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, GSK, Philip Morris, Atmosphere, HSX, Gold, Andon, AP, Blood pressure, Novartis, Brain, ASX, Alzheimer's disease, Yale University, Ecosystem, Technology, Arm, Health, Hypertension, AstraZeneca, ASF, CDX, DCT, Stroke, OTA, RPM, Risk, Clinical trial, CPT, Cardiovascular disease, Australian Securities Exchange, Physician, Medical device, Medical imaging, Pharmaceutical industry, Pulse, Bayer, ECAPS, GlaxoSmithKline

IRVINE, Calif., June 28, 2022 /PRNewswire/ -- CardieX Limited (ASX: CDX), a global health technology company focused on cardiovascular disease, has together with its manufacturing partner Andon filed a 510(k) premarket submission with the U.S. Food and Drug Administration (FDA) for the CONNEQT Pulse (Pulse)  – a world first dual blood pressure and arterial health monitor targeted at the home health, remote patient monitoring, and decentralized clinical trial markets.

Key Points: 
  • Pulse will also be the first blood pressure monitor to incorporate "over the air" (OTA) customizable display screens based on specific health parameters and disease conditions.
  • SphygmoCor technology has been in use for over 20 years by researchers, specialist clinicians, and pharmaceutical companies looking to obtain advanced arterial health insights beyond traditional blood pressure.
  • Measuring central blood pressure at the heart is considered to be superior to standard measurements of blood pressure at the arm mainly due to the proximity of the heart to the major organs.
  • Arterial Stiffness Factor (ASF): Based on Augmentation Pressure (AP) a clinical standard for measuring arterial stiffness, and other proprietary algorithms.

Global Systemic Lupus Erythematosus (SLE) Market Report 2022: Expected Value of $2.71 Billion by 2026, Growing from $1.89 Billion - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 28, 2022
Health, Biotechnology, Product, FDA, Centers for Disease Control and Prevention, Patient, Administration, GSK, Research, SLE, Adoption, Intravenous therapy, Hospital, COVID-19, Population, Growth, Urbanization, Center, Disease, Female, Prevalence, Awareness, Woman, CAGR, Organization, NMPA, Nonsteroidal anti-inflammatory drug, Medicine, Drug development, Government, Safety, US FDA, CDC, Route of administration, Pharmaceutical industry, Lupus, Belimumab

In 2021, the global systemic lupus erythematosus market was valued at US$1.89 billion.

Key Points: 
  • In 2021, the global systemic lupus erythematosus market was valued at US$1.89 billion.
  • The systemic lupus erythematosus market is expected to grow at a CAGR of 7.49% over the forecasted years 2022-2026.
  • Stringent regulatory environment is one of the major challenges to the systemic lupus erythematosus market.
  • Adoption of Stem cell therapy is increasing because this is a new and advance technique to treat lupus and that would boost the SLE market growth.

Dunad Therapeutics Appoints Industry Veteran Pearl Huang as Chief Executive Officer

Retrieved on: 
Tuesday, June 28, 2022
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Massachusetts Institute of Technology, Flagship Pioneering, GSK, Novartis, Technology, Senior, Waters Corporation, DPAC, Growth, CNS, Industry, Inflammation, BB Biotech, Merck, Therapy, Drug discovery, Roche, Molecular biology, Chemistry, Leadership, BGV, Princeton University, Doctor of Philosophy, Pharmaceutical industry

Dunad Therapeutics, a biopharmaceutical company developing small molecule covalent therapies based on novel insights from chemistry and protein degradation, today announced it has appointed Pearl Huang, Ph.D., as Chief Executive Officer.

Key Points: 
  • Dunad Therapeutics, a biopharmaceutical company developing small molecule covalent therapies based on novel insights from chemistry and protein degradation, today announced it has appointed Pearl Huang, Ph.D., as Chief Executive Officer.
  • Prior to Dunad, she was Chief Executive Officer and President of Cygnal Therapeutics, founded by Flagship Pioneering, where she was also a venture partner.
  • Dr. Huang serves on the board of directors for KSQ Therapeutics, Waters Corporation and BB Biotech, and is a member of the MIT Corporation.
  • Dunad Therapeutics is a biopharmaceutical company developing small molecule covalent therapies based on novel insights from chemistry and protein degradation.

Paul Fry appointed as Argenta’s new Chief Financial Officer

Retrieved on: 
Monday, June 27, 2022
Health, Research, Pharmaceutical, Science, Biotechnology, Veterinary, Gavin Downie, Acquisition, Vodafone, CEO, GSK, Research, KKR, Contract research organization, Telecommunication, Growth, Ownership, TCR, GMP, CDMO, CRO, CFO, Contract, London Stock Exchange, United Kingdom, Partnership, Asota avacta, Chartered Institute of Management Accountants, Technology, Management accounting, Vectura Group, University of Oxford, Health, Audit committee, Time, List of professional associations in the United Kingdom, Management, Renewable energy

Argenta today announced that Paul Fry will join the company as its new Chief Financial Officer, starting immediately.

Key Points: 
  • Argenta today announced that Paul Fry will join the company as its new Chief Financial Officer, starting immediately.
  • Paul Fry has extensive financial experience across several industries including biotech, pharmaceuticals, and telecommunications.
  • Before Vectura, Paul was Chief Financial Officer of Immunocore Limited, a leading biotech company focused on the development of a new class of immunotherapeutic drugs based on proprietary T-cell receptor (TCR) technology.
  • Paul Fry said: It is an exciting time to enter the animal health industry and I am delighted to be joining Argenta.